What is Retatrutide?

Retatrutide (development code LY3437943) is a synthetic peptide engineered as a triple agonist at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. The peptide is a 39-amino-acid sequence with a C20 fatty-diacid conjugate via a γ-Glu-2xAdo linker, enabling extended half-life through albumin binding.

For UK research laboratories, retatrutide serves as a reference compound for studies examining multi-receptor metabolic regulation, energy homeostasis, and the interplay between incretin and glucagon signalling in cellular and in vitro models.

Retatrutide activates three distinct receptor systems that collectively regulate metabolic physiology:

GLP-1 Receptor Agonism — Potentiates glucose-dependent insulin secretion, suppresses glucagon release in hyperglycaemic states, delays gastric emptying, and activates brainstem satiety circuits.

GIP Receptor Agonism — Amplifies insulin secretion in a glucose-dependent manner, promotes lipid storage in adipose tissue, and may support bone formation.

Glucagon Receptor Agonism — Increases hepatic glucose output, stimulates lipolysis, and raises energy expenditure. The glucagon component creates a counter-regulatory signal that balances the insulinotropic effects of GLP-1 and GIP.

Retatrutide is employed across multiple research domains in UK laboratories:

Metabolic Disease Research — In vitro studies examine insulin secretion, glucagon suppression, and glucose uptake in isolated islet and hepatocyte cultures.

Energy Homeostasis Studies — Cellular models of adipocyte differentiation, lipolysis, and thermogenesis are used to study energy balance effects.

Comparative Pharmacology — Retatrutide is frequently compared to single-agonist and dual-agonist peptides (tirzepatide, semaglutide) in cellular receptor-binding assays.

Receptor Pharmacology — The peptide serves as a tool compound for studying class B GPCR biology, receptor oligomerisation, and biased agonism.

Retatrutide is supplied as a lyophilised powder. Standard laboratory preparation:

• Bacteriostatic water (0.9% benzyl alcohol) recommended for reconstitution
• Typical concentrations: 1–10 mg/mL depending on assay requirements
• Solubility: The fatty-diacid conjugate may reduce aqueous solubility; gentle vortexing and brief warming (not exceeding 37°C) can aid dissolution
• Albumin binding: Account for this in binding assays and cellular incubations
• pH: Maintain solutions at pH 6.5–7.5

• Lyophilised powder: −20°C, protected from light
• Reconstituted solution: 2–8°C, protected from light
• Stability: 7–14 days under refrigeration; aliquot and freeze at −20°C for extended studies
• Avoid: Repeated freeze-thaw cycles